InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.027 -0.001 (-3.57%)+
Announcement
Release
27 Jul 2026 9:33AM
Price at Release
$0.028
Full Release
download
Summary
Firebrick Pharma Limited's investor update highlights the ongoing commercialization efforts and market expansion plans for Nasodine®, a nasal spray designed to kill viruses. The product, which has been launched in the USA and Singapore, is awaiting approval in Indonesia and the Philippines. It is marketed differently across regions due to varying regulatory classifications. Firebrick has completed its core R&D, thereby minimizing clinical risk, and plans further product launches, including a Nasodine Throat Spray. The company is focusing on licensing in regions with lower regulatory burdens to drive growth, aiming for approval or sales in ten markets within three years.
Key Points
  • Nasodine® Nasal Spray developed by Firebrick Pharma Limited is marketed as the first nasal spray that kills viruses.
  • The spray has been launched in the USA and Singapore with approvals pending in Indonesia and the Philippines.
  • Firebrick has completed core R&D for Nasodine®, reducing clinical risk.
  • The product is considered inexpensive with a price range of A$27-36 per unit, with Firebrick receiving A$2-3 per unit as a license fee.
  • Sales growth is targeted through licensing in markets with fewer regulatory barriers, especially Southeast Asia.
  • Nasodine® is classified differently in various markets, impacting its regulatory pathway.
  • Firebrick plans further product expansions with a Nasodine Throat Spray already launched.
  • The company anticipates its products to be approved or on sale in 10 markets within three years.
  • Future sales are expected to grow with the introduction of new products and market expansions.
  • The company has a strategic focus on markets where Nasodine can be sold with less regulatory burden.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.